Instrument Inactif

Communiqués iCAD Inc Nasdaq

Actions

US44934S1078

Equipement et technologie médicale avancés

Cours en clôture Nasdaq Autres places de cotation
- ^USD	-

17/07/25	RadNet finalise l'acquisition d'iCAD pour 99 millions de dollars	CI
17/07/25	DeepHealth, filiale de RadNet, finalise l'acquisition d'iCAD	MT

Communiqués

08/07/25	ICAD Announces Proxy Advisory Firms ISS and Glass Lewis Recommend Stockholders Vote “FOR” Proposed Acquisition by RadNet, Inc.	AQ
03/06/25	ICAD INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of iCAD, Inc. - ICAD	BU
13/05/25	ICAD Reports Financial Results for First Quarter Ended March 31, 2025	AQ
29/04/25	ICAD Collaborates with Microsoft to provide access to its Mammography Solutions in Microsoft’s Precision Imaging Network (PIN)	AQ
17/04/25	ICAD INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of iCAD, Inc. - ICAD	BU
15/04/25	RadNet, Inc. to Acquire iCAD, Inc. to Accelerate AI-Powered Early Detection and Diagnosis of Breast Cancer	AQ
08/04/25	ICAD Expands Executive Leadership with Appointment of Mark Koeniguer as Chief Commercial Officer	AQ
19/03/25	ICAD Reports Financial Results for Fourth Quarter and Fiscal Year Ended December 31, 2024	AQ
11/03/25	ICAD to Report Fourth Quarter and Full Year 2024 Financial Results on March 19, 2025	AQ
05/03/25	ICAD and RamSoft Announce Partnership to Deliver ProFound® AI-Powered Mammography Solutions Across North America	AQ
26/02/25	Koios Medical and iCAD Partner to Expand AI-Powered, Multi-Modality Breast Cancer Detection Solutions at ECR 2025	AQ
19/02/25	ICAD To Showcase Five AI-Powered Research Presentations Advancing Breast Cancer Detection, Risk Evaluation, and Breast Arterial Calcification Assessment at ECR 2025	AQ
27/01/25	ICAD Pre-Announces Estimated Q4 2024 Revenue	AQ
11/12/24	SABCS 2024: New Research Assesses iCAD’s Image Based AI-Risk, Detection, and Breast Arterial Calcifications (BAC) Assessment Across Diverse Populations	AQ
04/12/24	CORRECTION – iCAD Advances Fight Against Breast Cancer with FDA-cleared, Next-Generation AI Solutions and ProFound Health Partnership with Cascaid Health at RSNA 2024	AQ
26/11/24	ICAD Advances Fight Against Breast Cancer with FDA-cleared, Next-Generation AI Solutions and a Second-Read AI Partnership with Cascaid Health at RSNA 2024	AQ
13/11/24	ICAD : Reports Financial Results for Third Quarter Ended September 30, 2024 Form 8 K	PU
13/11/24	ICAD Reports Financial Results for Third Quarter Ended September 30, 2024	AQ
12/11/24	ICAD's ProFound Detection Version 4.0 Gains FDA Clearance	AQ
06/11/24	ICAD to Attend 15th Annual Craig-Hallum Alpha Select Conference	AQ
05/11/24	ICAD to Report Third Quarter 2024 Financial Results on November 13, 2024	AQ
16/10/24	ICAD to Participate in the LD Micro Main Event XVII	NE
03/10/24	ICAD Highlights Global Availability of ProFound Cloud and International Expansion Milestones at JFR 2024	AQ
12/09/24	ICAD to Participate in the iAccess Alpha Buyside Best Ideas Fall Conference 2024	AQ
11/09/24	ICAD to Participate in the iAccess Alpha Buyside Best Ideas Fall Conference 2024	AQ